Name | PHENAZOPYRIDINE HYDROCHLORIDE |
Synonyms |
sedural urazium uriplex pyrizin uridinal PYRIDACIL BISTERIL MALLOPHENE urobiotic-250 PHENAZODINE thiosulfil-aforte PHENAZOPYRIDINE HCL PHENAZOPYRIDINE HYDROCHLORIDE PHENYLAZODIAMINOPYRIDINE HYDROCHLORIDE 3-[(E)-phenyldiazenyl]pyridine-2,6-diamine 3-phenylazopyridine-2,6-diamine hydrochloride 3-PHENYLAZO-2,6-DIAMINOPYRIDINE HYDROCHLORIDE 2,6-DIAMINO-3-[PHENYLAZO]PYRIDINE HYDROCHLORIDE 2,6-diamino-3-(phenylazo)-pyridinmonohydrochloride 3-PHENYLAZO-2,6-DIAMINOPYRIDINE MONOHYDROCHLORIDE 3-BENZENEAZO-2,6-DIAMINOPYRIDINE MONOHYDROCHLORIDE 2,6-DIAMINO-3-(PHENYLAZO)PYRIDINE MONOHYDROCHLORIDE 3-(PHENYLAZO)-2,6-PYRIDINEDIAMINE, MONOHYDROCHLORIDE |
CAS | 136-40-3 |
EINECS | 205-243-8 |
InChI | InChI=1/C11H11N5.ClH/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8;/h1-7H,(H4,12,13,14);1H |
InChIKey | QQBPIHBUCMDKFG-GEEYTBSJSA-N |
Molecular Formula | C11H12ClN5 |
Molar Mass | 249.7 |
Density | 1.2645 (rough estimate) |
Melting Point | 139°C |
Boling Point | 394.6°C (rough estimate) |
Flash Point | 233.8°C |
Water Solubility | 0.01-0.1 g/100 mL at 20 ºC |
Solubility | Soluble in Methanol and Slightly Soluble in Cold Water |
Vapor Presure | 5.66E-09mmHg at 25°C |
Appearance | Powder |
Color | Clear to hazy colorless to yellow |
Merck | 14,7210 |
Storage Condition | Sealed in dry,2-8°C |
Refractive Index | 1.6110 (estimate) |
MDL | MFCD00035347 |
Physical and Chemical Properties | Light red to dark purple crystalline powder. |
Use | For the relief of cystitis, prostatitis, urethritis, gonorrheal urethritis and endoscopy, urethral intubation caused by the urethra and bladder pain, burning sensation and frequent urination, urgency and other discomfort |
In vitro study | Phenazopyridine:(I) enhances neural cell differentiation, (ii) increases cell survival, (iii) reduces the number of non-neuronal and undifferentiated cells and (iv) synchronizes the state of cell differentiation. |
In vivo study | Phenazopyridine can directly inhibit the mechanically sensitive A δ-fibers of normal rat bladder. |
Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. R40 - Limited evidence of a carcinogenic effect R34 - Causes burns R42/43 - May cause sensitization by inhalation and skin contact. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S27 - Take off immediately all contaminated clothing. S22 - Do not breathe dust. |
UN IDs | 2811 |
WGK Germany | 3 |
RTECS | US7875000 |
HS Code | 29333990 |
Toxicity | LD50 orally in rats: 403 mg/kg (Becker, Swift) |
This product is 2, 6-diamino-3-(phenylazo) pyridine hydrochloride. The content of C11H11N5.HC1 shall be between 98.0% and 102.0% based on the dry product.
take this product, precision weighing, adding mobile phase to dissolve and quantitatively dilute to make a solution containing about 0.5mg per lml as a test solution; Take 1ml for precision measurement, in a 100ml measuring flask, dilute to the scale with mobile phase, shake well, and use as a control solution; Take the appropriate amount of 2, 6-diaminopyridine reference product and aniline reference product respectively, and weigh them precisely, the mobile phase was added to dissolve and quantitatively dilute to prepare a mixed solution each containing about 1 UG and 0.5ug per 1ml as a control solution. According to the chromatographic conditions under the content determination item, the sample solution, the control solution and the reference solution were accurately measured, and the human liquid chromatograph was injected respectively, the chromatogram was recorded to 3 times of the retention time of the main component peak. If there are chromatographic peaks consistent with the retention time of 2, 6-diaminopyridine and aniline in the chromatogram of the test solution, the peak area shall be calculated according to the external standard method, 6-diaminopyridine shall not exceed 0.2%, aniline shall not exceed 0.1%; Other individual impurities shall not exceed 0.5 times (0.5%) of the main peak area of the control solution, the sum of the peak areas of other impurities shall not be greater than the main peak area of the control solution (1.0%).
take this product, dry to constant weight at 105°C, weight loss shall not exceed 1.0% (General rule 0831).
take 2.0g of this product, accurately weigh it, put it in a plug Erlenmeyer flask, add 200ml of water, heat it to boiling to dissolve it, and heat it on a water bath for 1 hour, while hot, filter through a No. 4 vertical melting crucible with constant weight at 105°C, fully wash with hot water, and dry at 105°C to constant weight. Residual flooding shall not exceed 0.1%.
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.2%.
The residue left under the item of taking the ignition residue shall not contain more than 20 parts per million of heavy metal when examined by law (General rule 0821, Law II).
measured by high performance liquid chromatography (General 0512).
with eighteen alkyl silane bonded silica gel as filler; Phosphate buffer solution (take diammonium hydrogen phosphate 2.64g, add water 900ml to dissolve, adjust the pH value with phosphoric acid to 3.0, add water to make 1000ml)-Fermentation broth (50:50) as mobile phase with detection wavelength at 240nm. Take appropriate amount of Phenazopyridine hydrochloride, 2, 6-diaminopyridine and aniline, add mobile phase to dissolve and dilute to make mixed solution containing about 0.5mg, lug and 0.5ug in each lml, 20ul was injected into the liquid chromatograph and the chromatogram was recorded. The number of theoretical plates was not less than 2000 ,2, 6-diaminopyridine peak based on Phenazopyridine peak, the degree of separation between the aniline peak and the Phenazopyridine peak should meet the requirements.
take the right amount of this product, precision weighing, plus mobile phase dissolution and quantitative dilution made in each lml containing about 0.1 mg solution, as the test solution, the precision amount of 20u1 injection of human liquid chromatography, record the chromatogram; Another hydrochloric acid Phenazopyridine reference substance, the same method for determination. According to the external standard method to calculate the peak area, that is.
pain medication for the urinary tract.
light-shielded, sealed, and stored in a dry place.
This product contains Phenazopyridine hydrochloride (C11H11N5 • HCI) should be labeled for the amount of 90.0% to 110.0%.
This product is sugar-coated tablet or film-coated tablet, after removing the coating appear brown red to dark red.
with Phenazopyridine hydrochloride.
O.lg
sealed and stored in a dry place.
(IARC) carcinogen classification | 2B (Vol. 24, Sup 7) 1987 |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
introduction | phenazide hydrochloride (Phenazopyridine) is an azide drug, which can relieve pain and discomfort to inflamed parts when excreted with urine after taking it. It has analgesic or local anesthetic effect on urinary tract mucosa. This product is excreted from the urine as a prototype after oral administration, and directly acts on the urinary tract mucosa to exert an analgesic effect. |
biological activity | Phenazopyridine HCl is a topical analgesic that has been used to treat urinary system diseases. It is an inhibitor of sodium channel protein type 1 subunit alpha. |
adverse reactions | gastrointestinal discomfort, headache and rash. Anemia, neutropenia, thrombocytopenia, kidney stones and nephrotoxic reactions have been reported. Occasionally abnormal liver function, hemolytic anemia, methemoglobinemia and acute renal failure have been reported. |
use | used to relieve urethra and bladder pain, burning sensation, frequent urination, urgent urination and other discomfort caused by cystitis, prostatitis, urethritis, gonorrhea urethritis, endoscopy, urethral intubation, etc. dark red crystalline powder |